上周（7月20日-7月24日），共有10支新股登陆上交所科创板，其中7月22日恰逢科创板开板一周年，当天更有7支新股“扎堆”上市。
- 7月20日，人工智能芯片制造商寒武纪在科创板成功上市，募资约25.82亿元人民币。中伦律师事务所担任发行人律师，嘉润律师事务所则为保荐人中信建投提供法律意见。
2016年创立于北京，寒武纪关注人工智能芯片产品的研发与技术创新，其产品广泛应用于消费电子、数据中心、云计算等场景。
中伦团队牵头律师为合伙人杨开广。 - 7月22日，网络安全服务商奇安信在科创板成功上市，募资约57亿元人民币。金杜律师事务所担任发行人律师，项目保荐人同样为中信建投。
2014年成立于北京，奇安信原为互联网公司360的政企安全部门，于2016年正式被分拆。其主营业务为向政府、企业客户提供新一代企业级网络安全产品和服务。
金杜团队牵头律师为合伙人龚牧龙、马天宁、黄晓雪、卢勇。 - 7月22日，生物医药企业三生国健在科创板成功上市，募资约17亿元人民币。中伦律师事务所担任发行人律师，方达律师事务所则为保荐人华泰联合证券提供法律意见。
三生国健是香港上市公司三生制药的控股子公司，三生制药于1993年成立于沈阳，2015年在港交所主板上市，三生国健也是首家港股医药上市公司分拆登陆科创板的生物医药企业，其主要关注于抗体药物研发，是目前唯一拥有三款治疗性抗体类药物的国内生物药企。
中伦团队牵头律师为合伙人陈益文。
STAR Mkt celebrates one-year anniversary with four firms leading deals in Week 52
The Shanghai STAR Market has celebrated its one-year anniversary in its fifty-second trading week (July 20 – July 24), which saw a competing team of ten IPOs in a single week.
- Zhong Lun Law Firm has advised AI chip maker Cambricon Technology on its $368 million initial public offering, with Dowway & Partners advising the sole sponsor China Securities.
Founded just in 2016 in Beijing, Cambricon focuses on the research and development of AI chips and its products are widely used in areas of e-commerce, data center and cloud computing.
The Zhong Lun team was led by partner Yang Kaiguang. - Meanwhile King & Wood Mallesons has advised cybersecurity firm Qi An Xin Technology on its $814 million IPO, with China Securities also acting as the sole sponsor.
Founded in 2014 in Beijing as a subsidiary of cybersecurity software giant Qihoo 360 Technology, Qi An Xin parted way with 360 in 2016. It provides cybersecurity services mainly to government agencies in Beijing.
The KWM team was led by partners Gong Mulong, Ma Tianning, Huang Xiaoxue and Lu Yong. - On the same day, Zhong Lun Law Firm has also represented biotech company Sunshine Guojian Pharmaceutical on its $243 million IPO, with Fangda Partners acting for the principal sponsor Huatai United Securities.
Guojian is a subsidiary of Hong Kong-listed 3SBio Group. It has developed three antibody drugs and the proceeds will be used for research and development of new drugs targeting oncology, autoimmunity and ophthalmic conditions.
The Zhong Lun team was led by partner Chen Yiwen.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.
